Loading…

A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

Background Phase I and II clinical trials have demonstrated acceptable toxicity and promising activity of Edatrexate (10-EDAM). The objective of this multicentre phase II study was to determine the efficacy and toxicity of this agent in patients with metastatic melanoma. Patients and methods Sixteen...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology 1993-03, Vol.4 (3), p.254-255
Main Authors: Verma, S., Quirt, I. C., Eisenhauer, E. A., Iscoe, N. A., Young, V. J., Bodurtha, A. J., Davidson, J.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Phase I and II clinical trials have demonstrated acceptable toxicity and promising activity of Edatrexate (10-EDAM). The objective of this multicentre phase II study was to determine the efficacy and toxicity of this agent in patients with metastatic melanoma. Patients and methods Sixteen previously untreated patients with metastatic melanoma received 10-EDAM, 80 mg/m2/week intravenously. Patients were evaluated for response and toxicity. Results There were no objective responses. The median dose intensity of 10-EDAM actually delivered was 56.25 mg/m2/week (70% of projected). Mucositis of any degree was encountered in 93.8% of patients. Grade 3 or 4 mucositis, skin rash, nausea, abdominal pain, neutropenia, thrombocytopenia, anemia and hyperbilirubinemia each were encountered in 1–2 patients. There was 1 toxic death due to 10-EDAM. Conclusion 10-EDAM is an inactive agent in metastatic melanoma.
ISSN:0923-7534
1569-8041
DOI:10.1093/oxfordjournals.annonc.a058467